Abstract
Our previous study revealed that compound 1 (9-(4'-hydroxy-4-biphenyl)acetamido-9-deoxy-Neu5Gcalpha2-6GalOMP) has the most promising affinity for mCD22. Replacing the subterminal galactose residue of 1 with benzyl or biphenylmethyl as aglycone led to 38- and 20-fold higher potency, respectively. This discovery represents a new direction in inhibitor design suitable for pharmaceutical development.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Biphenyl Compounds / chemical synthesis
-
Biphenyl Compounds / chemistry*
-
Biphenyl Compounds / pharmacology
-
Disaccharides / chemical synthesis
-
Disaccharides / chemistry*
-
Disaccharides / pharmacology
-
Mice
-
N-Acetylneuraminic Acid / chemistry*
-
Sialic Acid Binding Ig-like Lectin 2 / chemistry*
-
Sialic Acid Binding Ig-like Lectin 2 / metabolism
Substances
-
Biphenyl Compounds
-
Disaccharides
-
Sialic Acid Binding Ig-like Lectin 2
-
N-Acetylneuraminic Acid